Adverse Effects of Digoxin, As Xenoestrogen, on Some Hormonal and Biochemical Patterns of Male Albino Rats Eman G.E.Helal *, Mohamed M.M
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Dilantin (Phenytoin Sodium) Extended Oral Capsule Three Times Daily and the Dosage Then Adjusted to Suit Individual Requirements
Dilantin® (Phenytoin Sodium) 100 mg Extended Oral Capsule DESCRIPTION Phenytoin sodium is an antiepileptic drug. Phenytoin sodium is related to the barbiturates in chemical structure, but has a five-membered ring. The chemical name is sodium 5,5-diphenyl-2, 4-imidazolidinedione, having the following structural formula: Each Dilantin— 100 mg Extended Oral Capsule—contains 100 mg phenytoin sodium. Also contains lactose monohydrate, NF; confectioner’s sugar, NF; talc, USP; and magnesium stearate, NF. The capsule body contains titanium dioxide, USP and gelatin, NF. The capsule cap contains FD&C red No. 28; FD&C yellow No. 6; and gelatin NF. Product in vivo performance is characterized by a slow and extended rate of absorption with peak blood concentrations expected in 4 to 12 hours as contrasted to Prompt Phenytoin Sodium Capsules, USP with a rapid rate of absorption with peak blood concentration expected in 1½ to 3 hours. CLINICAL PHARMACOLOGY Phenytoin is an antiepileptic drug which can be used in the treatment of epilepsy. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Possibly by promoting sodium efflux from neurons, phenytoin tends to stabilize the threshold against hyperexcitability caused by excessive stimulation or environmental changes capable of reducing membrane sodium gradient. This includes the reduction of posttetanic potentiation at synapses. Loss of posttetanic potentiation prevents cortical seizure foci from detonating adjacent cortical areas. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (grand mal) seizures. The plasma half-life in man after oral administration of phenytoin averages 22 hours, with a range of 7 to 42 hours. -
Is an Activator of the Human Estrogen Receptor Alpha
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Newcastle University E-Prints 1 The ionic liquid 1-octyl-3-methylimidazolium (M8OI) is an activator of the human estrogen receptor alpha Alistair C. Leitch1, Anne F. Lakey1, William E. Hotham1, Loranne Agius1, George E.N. Kass2, Peter G. Blain1, Matthew C. Wright1,* 1Institute Cellular Medicine, Health Protection Research Unit, Level 4 Leech, Newcastle University, Newcastle Upon Tyne, United Kingdom NE24HH. 2European Food Safety Authority, Via Carlo Magno 1A, 43126 Parma, Italy. *Corresponding author. Address: Institute Cellular Medicine, Level 4 Leech Building; Newcastle University, Framlington Place, Newcastle Upon Tyne, UK. [email protected] Email addresses: [email protected] (A. Leitch), [email protected] (A. Lakey), [email protected] (W. Hotham), [email protected] (L Aguis), , [email protected] (G Kass), [email protected] (P. Blain) [email protected] (M. Wright). Abbreviations AhR, aryl hydrocarbon receptor; ICI182780, also known as fulvestrant; E2, 17β estradiol; EE, ethinylestradiol; ERα, estrogen receptor alpha, also known as NR3A1; ERβ, estrogen receptor beta, also known as ER3A2; M8OI, 1-octyl-3-methylimidazolium chloride, also known as C8min; PBC, primary biliary cholangitis; PPARα, peroxisome proliferator activated receptor alpha; TFF1, trefoil factor 1. 2 ABSTRACT Recent environmental sampling around a landfill site in the UK demonstrated that unidentified xenoestrogens were present at higher levels than control sites; that these xenoestrogens were capable of super-activating (resisting ligand-dependent antagonism) the murine variant 2 ERβ and that the ionic liquid 1-octyl-3-methylimidazolium chloride (M8OI) was present in some samples. -
Memorandum Date: June 6, 2014
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Memorandum Date: June 6, 2014 From: Bisphenol A (BPA) Joint Emerging Science Working Group Smita Baid Abraham, M.D. ∂, M. M. Cecilia Aguila, D.V.M. ⌂, Steven Anderson, Ph.D., M.P.P.€* , Jason Aungst, Ph.D.£*, John Bowyer, Ph.D. ∞, Ronald P Brown, M.S., D.A.B.T.¥, Karim A. Calis, Pharm.D., M.P.H. ∂, Luísa Camacho, Ph.D. ∞, Jamie Carpenter, Ph.D.¥, William H. Chong, M.D. ∂, Chrissy J Cochran, Ph.D.¥, Barry Delclos, Ph.D.∞, Daniel Doerge, Ph.D.∞, Dongyi (Tony) Du, M.D., Ph.D. ¥, Sherry Ferguson, Ph.D.∞, Jeffrey Fisher, Ph.D.∞, Suzanne Fitzpatrick, Ph.D. D.A.B.T. £, Qian Graves, Ph.D.£, Yan Gu, Ph.D.£, Ji Guo, Ph.D.¥, Deborah Hansen, Ph.D. ∞, Laura Hungerford, D.V.M., Ph.D.⌂, Nathan S Ivey, Ph.D. ¥, Abigail C Jacobs, Ph.D.∂, Elizabeth Katz, Ph.D. ¥, Hyon Kwon, Pharm.D. ∂, Ifthekar Mahmood, Ph.D. ∂, Leslie McKinney, Ph.D.∂, Robert Mitkus, Ph.D., D.A.B.T.€, Gregory Noonan, Ph.D. £, Allison O’Neill, M.A. ¥, Penelope Rice, Ph.D., D.A.B.T. £, Mary Shackelford, Ph.D. £, Evi Struble, Ph.D.€, Yelizaveta Torosyan, Ph.D. ¥, Beverly Wolpert, Ph.D.£, Hong Yang, Ph.D.€, Lisa B Yanoff, M.D.∂ *Co-Chair, € Center for Biologics Evaluation & Research, £ Center for Food Safety and Applied Nutrition, ∂ Center for Drug Evaluation and Research, ¥ Center for Devices and Radiological Health, ∞ National Center for Toxicological Research, ⌂ Center for Veterinary Medicine Subject: 2014 Updated Review of Literature and Data on Bisphenol A (CAS RN 80-05-7) To: FDA Chemical and Environmental Science Council (CESC) Office of the Commissioner Attn: Stephen M. -
THE SPECIFICITY of DRUG BINDING SITES on HUMAN SERUM ALBUMIN Ingvar Sjòholm
THE SPECIFICITY OF DRUG BINDING SITES ON HUMAN SERUM ALBUMIN Ingvar Sjòholm Today, it is well established that the binding of drugs in serum will strongly influence the pharmacokinetic parameters of a drug, such as its distribution volume and clearance. It is also evident that the binding of the drug—in serum and elsewhere in the tissues—will have an influence on the duration and intensity of the pharmacological effect. Several excellent papers and reviews have dealt with these issues in recent years.1"** It is obvious that albumin, being the most abundant protein species in the extracellular fluids, is the most im- portant drug-binding protein, although other proteins can play a pharmacokinetic role. Thus, e.g., orosomucoid (aj-acid glyco- protein) can bind some basic and neutral drugs ,9 and lipoproteins some highly hydrophobic drugs.10 The primary structure of human serum albumin (HSA) is now known.1:L'^2 However, all efforts to study the three-dimensional structure by x-ray spectroscopy have hitherto failed, and a detailed knowledge of the mechanisms involved in the binding of drugs or endogenous compounds is still missing. The broad binding specificity of HSA is remarkable. Several compounds of widely different struc- ture can be bound with high affinity—e.g., fatty acids, bilirubin, tryptophan, as well as many drugs. It is also striking that different reports from quantitative studies on the binding of different com- pounds have shown varying results, which cannot be solely explained by technical problems or different experimental conditions. All avail- able information indicates that HSA is a highly "flexible" and "adapt- able" molecule, the structure of which can be strongly influenced by different "modulating" substances. -
NINDS Custom Collection II
ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC -
Decreased Serum Concentrations of Tamoxifen and Its Metabolites Induced by Aminoglutethimide1
(CANCER RESEARCH 50. 5851-5857. September 15. 1990) Decreased Serum Concentrations of Tamoxifen and Its Metabolites Induced by Aminoglutethimide1 Ernst A. Lien,2 Gun Anker, Per Eystein Lgnning, Einar Solheim, and Per M. Ueland Department i>j'Pharmacology and Toxicology [E. A. I... E. S]; Clinical Pharmacology I nit. Department of Pharmacology and Toxicology /P. M. l './; and Department of Oncology I(i. A., P. fi. Lj, L'niversity of Bergen, .\-502l, Bergen, \onvay ABSTRACT Aminoglutethimide inhibits the enzyme aromatase, which converts androgens to estrogens in peripheral fat tissue (3). The anticstrogen tamoxifen and the aromatase inhibitor aminoglute- This conversion is the main estrogen source in postmenopausal thimide show similar response rates when used in the endocrine manage women. In addition, aminoglutethimide may reduce the con ment of advanced breast cancer. However, numerous clinical trials have centration of plasma estrogens by enhancement of estrogen demonstrated no increase in response rate from treatment with the drug combination of tamoxifen plus aminoglutethimide. We investigated the metabolism (10, 11). Aminoglutethimide causes response rates possibility of a pharmacokinetic interaction between these two drugs in in postmenopausal breast cancer patients similar to those of six menopausa! woman with breast cancer. All patients were investigated tamoxifen, but because of more frequent side effects aminoglu under three different conditions (termed phases A, B, and C). The steady tethimide is generally used after tamoxifen as a second line state kinetics of tamoxifen were determined when administered alone endocrine treatment (12). (phase A) and after coadministration of aminoglutethimide for 6 weeks Combination therapy with tamoxifen plus aminoglutethi (phase B). -
Estrogen Receptors in Polycystic Ovary Syndrome
cells Review Estrogen Receptors in Polycystic Ovary Syndrome Xue-Ling Xu 1,†, Shou-Long Deng 2,3,†, Zheng-Xing Lian 1,* and Kun Yu 1,* 1 College of Animal Science and Technology, China Agricultural University, Beijing 100193, China; [email protected] 2 Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences, Ministry of Health, Beijing 100021, China; [email protected] 3 CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, China * Correspondence: [email protected] (Z.-X.L.); [email protected] (K.Y.) † These authors contributed equally to this work. Abstract: Female infertility is mainly caused by ovulation disorders, which affect female reproduction and pregnancy worldwide, with polycystic ovary syndrome (PCOS) being the most prevalent of these. PCOS is a frequent endocrine disease that is associated with abnormal function of the female sex hormone estrogen and estrogen receptors (ERs). Estrogens mediate genomic effects through ERα and ERβ in target tissues. The G-protein-coupled estrogen receptor (GPER) has recently been described as mediating the non-genomic signaling of estrogen. Changes in estrogen receptor signaling pathways affect cellular activities, such as ovulation; cell cycle phase; and cell proliferation, migration, and invasion. Over the years, some selective estrogen receptor modulators (SERMs) have made substantial strides in clinical applications for subfertility with PCOS, such as tamoxifen and clomiphene, however the role of ER in PCOS still needs to be understood. This article focuses on the recent progress in PCOS caused by the abnormal expression of estrogen and ERs in the ovaries and uterus, and the clinical application of related targeted small-molecule drugs. -
Structural and Mechanistic Insights Into Bisphenols Action Provide Guidelines for Risk Assessment and Discovery of Bisphenol a Substitutes
Structural and mechanistic insights into bisphenols action provide guidelines for risk assessment and discovery of bisphenol A substitutes Vanessa Delfossea, Marina Grimaldib, Jean-Luc Ponsa, Abdelhay Boulahtoufb, Albane le Mairea, Vincent Cavaillesb, Gilles Labessea, William Bourgueta,1,2, and Patrick Balaguerb,1,2 aCentre de Biochimie Structurale, Institut National de la Santé et de la Recherche Médicale U1054, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5048, Universités Montpellier 1 and 2, 34090 Montpellier, France; and bInstitut de Recherche en Cancérologie de Montpellier, Institut National de la Santé et de la Recherche Médicale U896, Centre Régional de Lutte contre le Cancer Val d’Aurelle Paul Lamarque, Université Montpellier 1, 34298 Montpellier, France Edited* by Jan-Åke Gustafsson, Karolinska Institutet, Huddinge, Sweden, and approved August 2, 2012 (received for review March 1, 2012) Bisphenol A (BPA) is an industrial compound and a well known onset of obesity and other metabolic syndromes (9). In this regard, endocrine-disrupting chemical with estrogenic activity. The wide- a large body of data about endocrine-disrupting chemicals (EDCs) spread exposure of individuals to BPA is suspected to affect a variety underlines the importance of exposure during early stages of de- of physiological functions, including reproduction, development, and velopment, which could result in numerous biological defects in metabolism. Here we report that the mechanisms by which BPA and adult life (10). two congeners, bisphenol AF and bisphenol C (BPC), bind to and The molecular basis behind the deleterious effects of BPA is poorly understood, and a large controversy has been created activate estrogen receptors (ER) α and β differ from that used by 17β- within the field of endocrine disruption about low doses’ effects estradiol. -
Expressomal Approach for Comprehensive Analysis and Visualization of Ligand Sensitivities of Xenoestrogen Responsive Genes
Expressomal approach for comprehensive analysis and visualization of ligand sensitivities of xenoestrogen responsive genes Toshi Shiodaa,b,1, Noël F. Rosenthala, Kathryn R. Cosera, Mizuki Sutoa, Mukta Phatakc, Mario Medvedovicc, Vincent J. Careyb,d, and Kurt J. Isselbachera,b,1 aMolecular Profiling Laboratory, Massachusetts General Hospital Center for Cancer Research, Charlestown, MA 02129; bDepartment of Medicine, Harvard Medical School, Boston, MA 02115; cLaboratory for Statistical Genomics and Systems Biology, Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH 45267; and dChanning Laboratory, Brigham and Women’s Hospital, Boston, MA 02115 Contributed by Kurt J. Isselbacher, August 26, 2013 (sent for review June 17, 2013) Although biological effects of endocrine disrupting chemicals Evidence is accumulating that the EDCs may cause significant (EDCs) are often observed at unexpectedly low doses with occa- biological effects in humans or animals at doses far lower than sional nonmonotonic dose–response characteristics, transcriptome- the exposure limits set by regulatory agencies (8, 9). In addition wide profiles of sensitivities or dose-dependent behaviors of the to such low-dose effects, an increasing number of studies also EDC responsive genes have remained unexplored. Here, we describe support the concept of the nonmonotonic EDC effects, whose dose–response curves show U shapes or inverted-U shapes (8- expressome analysis for the comprehensive examination of dose- – dependent gene responses -
Application of Various Molecular Modelling Methods in the Study of Estrogens and Xenoestrogens
International Journal of Molecular Sciences Review Application of Various Molecular Modelling Methods in the Study of Estrogens and Xenoestrogens Anna Helena Mazurek 1 , Łukasz Szeleszczuk 1,* , Thomas Simonson 2 and Dariusz Maciej Pisklak 1 1 Chair and Department of Physical Pharmacy and Bioanalysis, Department of Physical Chemistry, Medical Faculty of Pharmacy, University of Warsaw, Banacha 1 str., 02-093 Warsaw Poland; [email protected] (A.H.M.); [email protected] (D.M.P.) 2 Laboratoire de Biochimie (CNRS UMR7654), Ecole Polytechnique, 91-120 Palaiseau, France; [email protected] * Correspondence: [email protected]; Tel.: +48-501-255-121 Received: 21 July 2020; Accepted: 1 September 2020; Published: 3 September 2020 Abstract: In this review, applications of various molecular modelling methods in the study of estrogens and xenoestrogens are summarized. Selected biomolecules that are the most commonly chosen as molecular modelling objects in this field are presented. In most of the reviewed works, ligand docking using solely force field methods was performed, employing various molecular targets involved in metabolism and action of estrogens. Other molecular modelling methods such as molecular dynamics and combined quantum mechanics with molecular mechanics have also been successfully used to predict the properties of estrogens and xenoestrogens. Among published works, a great number also focused on the application of different types of quantitative structure–activity relationship (QSAR) analyses to examine estrogen’s structures and activities. Although the interactions between estrogens and xenoestrogens with various proteins are the most commonly studied, other aspects such as penetration of estrogens through lipid bilayers or their ability to adsorb on different materials are also explored using theoretical calculations. -
Colosorm2003-Endosulfan.Pdf
Endosulfan: a hidden menace. Item Type Journal Contribution Authors Coloso, Relicardo M. Download date 02/10/2021 12:15:35 Link to Item http://hdl.handle.net/1834/8913 AsianSEAFDEC Aquaculture Volume XXV Number 2 April - June 2003 ISSN 0115-4974 ASEAN-SEAFDEC 5-YEAR PROGRAM Integrated Regional Aquaculture Project Endosulfan: a hidden menace Relicardo M. Coloso, Ph.D. Scientist II, SEAFDEC/AQD rmcoloso@ aqd.seafdec.org.ph The use of pesticides in agriculture and human health has been successful in controlling pests and diseases. The application of the organochlorine pesticides such as DDT [ 1, 1, 1-trichloro-2-2-bis(parachlorophenyl)ethane] against the malaria mosquito and many other insect pests provided a cheap and effective control for most insect problems. The new pesticide technology also brought in other effective agents such as herbicides (for weeds), avicides (for birds), piscicides (for fish), and molluscicides (for snails) that contributed to the success of farming systems worldwide. But pesticide application has many problems such as the emergence of new pests, persistence in the environment, environmental contamination, and subsequent effect on non-target organismsIRAP activity launched including humans. b y W G Yapa n dV T Sulit The chemical structure of endosulfan. After some delay due to various reasons the Endosulfan is highly toxic; it is either latest of which was the SARS outbreak, the restricted, not allowed in ricefields, Integrated Regional Aquaculture Project or banned in Southeast Asian (IRAP) under the ASEAN-SEAFDEC Special countries. Illegal trade and incorrect use 5-year Program had a soft launching with the (eg. to control golden apple snail in rice first phase of the site visitation and survey con paddies) always pose added danger ducted from 12 to 23 May 2003. -
A Critical Appraisal of a Further Three New Commercial Digoxin Radioimmunoassay Kits with Reference to Cross-Reacting Substances
Wood and Wächter: Appraisal of three digoxin radioimmunoassay kits 77 J. Clin. Chern. Clin. Biochem. Vol. 17,1979, pp. 77-83 A Critical Appraisal of a Further Three New Commercial Digoxin Radioimmunoassay Kits with Reference to Cross-Reacting Substances By W. G. Wood and Christine Wächter Laboratorien für Klinische Chemie und Endokrinologie, Medizinische Klinik Innenstadt der Universität München (Received July 20/September 11, 1978) Summary: A further 3 digoxin radioimmunoassay (RIA) kits have been evaluated for performance and cross-reaction with digitoxin, spironolactone, canrenone and furosemide (Lasix-Hoechst). Effects of serum protein concentrations have also been tested. The kits tested were from the following manufacturers: A) Diagnostic Products Corporation Digoxin RIA Kit. B) Byk-Mallinckrodt SPAC Digoxin Kit. C) Boehringer-Mannheim Digoxin RIA Kit. All kits used a 125I-labelled tracer. Kit A used a conventional liquid phase system using double-antibody separation for bound and free drug, Kits B and C used a solid-phase antibody coated tube method. All kits showed a lower cross-reaction to digitoxin than quoted by the manufacturer. Cross-reaction to spironolactone (Aldactone — Boehringer-Mannheim) was less than 1.50 nmol/I at a serum concentra- tion of 125 mg/1 Aldactone in all 3 kits. The cross-reaction to canrenone was somewhat higher, 5.2 nmol/1 "digoxin" being measured in one kit at a serum canrenone concentration of 125 mg/1. There was no cross-reaction with furo- semide in any kit, even at ä serum concentration of 5 g/1. The coated-tube assays were affected by serum albumin and globulin concentration changes, one kit showing a difference of over 50% binding in the range 1—20% albumin.